The European Union’s 2023 order has finally been carried out. GRAIL, Inc. is now a standalone company, fully separated from Illumina as of June 24, 2024. The divorce, three years after the marriage, resets the chessboard for early cancer detection.
GRAIL was founded in 2015 to chase a specific, difficult goal: find cancer in people who feel perfectly fine. Its tool is the Galleri test, a liquid biopsy launched in June 2021 that screens for multiple cancers from a single blood draw. The test represents a bet that catching tumors before symptoms appear can change outcomes. Illumina bought GRAIL in 2021, seeing the startup as a strategic fit for its DNA-sequencing technology. EU regulators saw a monopoly threat and told Illumina to let go.
The spin-out leaves GRAIL with its mission intact but its financial scaffolding removed. Under Illumina, GRAIL had access to deep pockets and a global sales network. Now it must fund its own operations, pay its own researchers, and sell its own tests. The company has not yet turned a profit. The Galleri test is not cheap, and widespread insurance coverage remains patchy. GRAIL will need to convince health systems and payers that early detection of multiple cancers at once is worth the upfront cost.
For patients, the consequences are indirect but real. A financially independent GRAIL could move faster or slower than it did as a subsidiary. Freed from Illumina’s corporate priorities, the company can pursue its own research partnerships and clinical trials. But it also loses the safety net. If the Galleri test does not gain traction quickly, there is no parent company to absorb the losses.
The competitive landscape shifts too. Other liquid biopsy companies—Guardant Health, Exact Sciences, Freenome—now face a GRAIL that is leaner and potentially more aggressive. The spin-out removes the perception that Illumina was giving its own test preferential access to sequencing technology. Rivals may see a more level playing field.
Regulators won. The EU directive was clear: Illumina’s acquisition of GRAIL risked stifling innovation in the emerging multi-cancer screening market. By forcing the separation, European authorities aimed to keep the field open. Whether that bet pays off depends on what GRAIL does next.
The company has not announced a public offering or new funding round. It has not named a new CEO separate from Illumina’s leadership. The immediate consequence of June 24 is uncertainty. GRAIL exists alone for the first time since 2021, carrying a promising test and a high burn rate.
What to watch: adoption numbers for the Galleri test. If GRAIL can show that its screening reduces late-stage cancer diagnoses and saves money for health systems, it will attract investors. If adoption stalls, the company may face a hard road. The EU’s order was about preserving competition. Now the market gets to decide if GRAIL’s product is worth the price of independence.
